share_log

智飞生物(300122.SZ):佐剂四价流感疫苗获临床试验批准

Chongqing Zhifei Biological Products (300122.SZ): Adjuvanted Quadrivalent Influenza Vaccine Approved for Clinical Trials.

Zhitong Finance ·  Oct 25, 2024 11:22

Chongqing Zhifei Biological Products (300122.SZ) announced that its wholly-owned subsidiary, Anhui Zhifei Longkema Biopharmaceutical Co., Ltd., developed...

According to the Zhongtong Finance and Economics APP, Chongqing Zhifei Biological Products (300122.SZ) announced that the quadrivalent influenza virus split vaccine (ZFA02 adjuvant) developed by its wholly-owned subsidiary, Anhui Zhifei Longkema Biopharmaceutical Co., Ltd., has obtained the approval notice for clinical trials of preventive vaccines for influenza caused by epidemic strains of influenza virus from the National Medical Products Administration.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment